- Amneal Pharmaceuticals, Inc. is a diversified biopharmaceutical leader based in Bridgewater, New Jersey, focusing on affordable medicines, including complex generics, injectables, biosimilars, and specialty products, with over 290 offerings in its portfolio.
- In April 2026, Amneal launched its first two metered-dose inhalation products in the U.S., albuterol sulfate inhalation aerosol and beclomethasone dipropionate HFA inhalation aerosol, marking its entry into the complex inhalation category.
- Amneal delivers over 160 million prescriptions annually and has established partnerships across various healthcare systems to enhance patient access to essential medicines.
- The ideal buyer for Amneal's products includes healthcare providers and institutions seeking affordable and effective treatment options for chronic conditions, particularly in the respiratory category, as evidenced by their recent product launches addressing unmet medical needs.
Amneal Pharmaceuticals has a diverse departmental structure, with 18 distinct departments contributing to its operations. The largest departments include Information Technology with 261 employees, Operations at 220, and Executive roles comprising 199 individuals. This distribution reflects a strong emphasis on technology and operational efficiency, while also maintaining a robust executive presence to guide strategic initiatives. The balance across departments suggests a well-rounded approach to workforce management.
The company's workforce is geographically distributed across 146 locations, with notable concentrations in New Jersey. The top locations include Paterson, NJ with 134 employees, East Hanover, NJ housing 103, and Parsippany, NJ with 101 employees. This concentration in New Jersey highlights the state's significance in Amneal's operational strategy, while the 'Other' category, comprising 940 employees, indicates a broad geographic reach that supports a distributed workforce model.
